fbpx

News

ThermoGenesis Holdings Announces Financial Results for the Third Quarter Ended September 30, 2020 and Provides Corporate Update

Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., Nov 12, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced financial and operating results for the third quarter ended September 30, 2020 … Continued

ThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2020 and Provide a Corporate Strategic Update

Conference Call to be Held on November 12, 2020 RANCHO CORDOVA, Calif., November 5, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the third quarter ended September 30, 2020 … Continued

Breaking Down ThermoGenesis’ Recent Patent for Its Breakthrough Serological Test Reader Technology

ThermoGenesis recently announced that the United States Patent and Trademark Office (USPTO) has accepted a patent application for the company’s new breakthrough lateral flow immunoassay test reader technology.   What is an Antibody Lateral Flow Immunoassay Test? An antibody lateral flow immunoassay (LFIA) test is a simple diagnostic device used to confirm the presence or … Continued

Facilitating the ‘Vaccine Era’ of COVID-19 Response: ThermoGenesis to Receive U.S. Patent for Breakthrough Serological Test Reader Technology

RANCHO CORDOVA, Calif., October 20, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO) today announced that it has received notification from the United States Patent and Trademark Office (USPTO) of its intent to issue U.S. Patent No. 10,823,746 on November 3, for the Company’s new breakthrough lateral flow immunoassay test reader technology, the ThermoGenesis Reader. The … Continued

ThermoGenesis Unveils Comprehensive Suite of Products and Services to Fight the Global COVID-19 Pandemic

RANCHO CORDOVA, Calif., Sept 2, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, along with its joint venture, ImmuneCyte, Inc. today announced plans to roll out a comprehensive diagnostic and therapeutic product line to fight the global COVID-19 pandemic. The multi-pronged … Continued

ThermoGenesis Distributes FDA Emergency Use Authorized COVID-19 Antibody Test Kit. What Does it Mean?

ThermoGenesis recently announced it has entered into a supply agreement with Biohit Healthcare to distribute its COVID-19 Antibody Test Kit. This agreement is significant because  Biohit Healthcare has already received Emergency Use Authorization from the U.S. Food and Drug Administration.   What is Emergency Use Authorization? The U.S. Food and Drug Administration (FDA) plays an … Continued

ThermoGenesis Holdings to Participate in Investor Conferences in September

RANCHO CORDOVA, Calif., Aug. 31, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced management’s participation in the following investor conferences in September.   September 1-4: LD Micro 500. Chris Xu, Ph.D., Chief Executive Officer of ThermoGenesis, will present … Continued

The Technology Behind Cord Blood Processing: AXP® II System

Cells are the basic building blocks of all biological life. Within these cells are small sections of proteins in DNA that possess all our genetic information, called genes. According to The Human Genome Project, it’s estimated that humans have between 20,000 and 25,000 genes. These genes all carry vital instructions for making proteins, which in … Continued

Convalescent Plasma Therapy for Coronavirus Patients

As scientists around the world work tirelessly to design new medicines for COVID-19, doctors have turned to convalescent plasma therapy to see if it could be a viable treatment option for coronavirus. While conservative measurements place the widespread availability of a coronavirus vaccine around somewhere in early 2021, convalescent plasma may potentially serve as a … Continued

How may we help?